G207
AXP000074.1 · Oncolytic virus
- Platform
- HSV-1 (strain F, gamma34.5-deleted, ICP6-inactivated)
- Originator
- Georgetown University (Robert Martuza)
- Sponsor
- Treovir LLC
Names
Virus
- Role
- Oncolytic
- Family
- Orthoherpesviridae
- Virus
- herpes simplex virus 1 (NCBI Taxonomy 10298)
- Strain
- F
- Replication
- conditionally replicating
- Modifications
- both copies of gamma34.5 (RL1) deleted; UL39 (ICP6) inactivated by lacZ insertion
- Transgenes
- LacZ
- Route
- intratumoral, intracerebral
- Source
- evidence
Cross-references
- NCI Thesaurus
- C2676
Approvals
No regulatory approval recorded.
Clinical trials (6)
| Trial | Title | Status | Phase | Start | Primary completion | Enrolment | Conditions |
|---|---|---|---|---|---|---|---|
| NCT07649070 | Phase 2 Trial of G207 + 5 Gy Radiation for Children With High-Grade Gliomas | Recruiting | Phase 2 | 2026-10-12 | 2030-12-31 | 38 | High Grade Gliomas |
| NCT04482933 | HSV G207 With a Single Radiation Dose in Children With Recurrent High-Grade Glioma | Withdrawn | Phase 2 | 2025-09-01 | 2025-12-18 | 0 | Anaplastic Astrocytoma of Brain; Anaplastic Glioma; Giant Cell Glioblastoma; Glioblastoma Multiforme; High Grade Glioma; High-grade Glioma; Malignant Glioma of Brain; Neoplasms |
| NCT03911388 | HSV G207 in Children With Recurrent or Refractory Cerebellar Brain Tumors | Recruiting | Phase 1 | 2019-09-12 | 2026-09-01 | 24 | Astrocytoma; Astrocytoma, Cerebellar; Brain Diseases; Central Nervous System Diseases; Central Nervous System Neoplasms, Malignant; Central Nervous System Neoplasms, Primary; Cerebellar Neoplasm Malignant Primary; Cerebellar Neoplasm, Malignant; Cerebellar Neoplasms; Cerebellar Neoplasms, Primary; Cerebellar PNET, Childhood; Glioblastoma Multiforme; Glioblastoma of Cerebellum; HSV; Medulloblastoma Recurrent; Neoplasm Malignant; Neoplasm Metastases; Neoplasms; Neoplasms by Histologic Type; Neoplasms by Site; Neoplasms, Brain; Neoplasms, Germ Cell and Embryonal; Neoplasms, Glandular and Epithelial; Neoplasms, Nerve Tissue; Neoplasms, Neuroepithelial; Nervous System Cancer; Nervous System Diseases; Nervous System Neoplasms; Neuroectodermal Tumors; Neuroectodermal Tumors, Primitive; Pediatric Brain Tumor; Primitive Neuroectodermal Tumor (PNET) of Cerebellum; Virus |
| NCT02457845 | HSV G207 Alone or With a Single Radiation Dose in Children With Progressive or Recurrent Supratentorial Brain Tumors | Completed | Phase 1 | 2016-05 | 2020-06 | 13 | Anaplastic Astrocytoma; Cerebral Primitive Neuroectodermal Tumor; Embryonal Tumor; Glioblastoma; Malignant Glioma; PNET; Supratentorial Neoplasms, Malignant |
| NCT00157703 | G207 Followed by Radiation Therapy in Malignant Glioma | Completed | Phase 1 | 2005-05 | 2008-10 | 9 | Malignant Glioma |
| NCT00028158 | Safety and Effectiveness Study of G207, a Tumor-Killing Virus, in Patients With Recurrent Brain Cancer | Completed | Phase 1/2 | 2001-12 | 65 | Astrocytoma; Glioblastoma; Glioma |
Recent changes
No changes recorded in its trials yet.
Clinical papers
| PubMed | Title | Journal | Year | Linked by |
|---|---|---|---|---|
| PMID 33838625 | Oncolytic HSV-1 G207 Immunovirotherapy for Pediatric High-Grade Gliomas. | The New England journal of medicine | 2021 | cited by trial NCT02457845 |
| PMID 32657154 | Design and Rationale for First-in-Human Phase 1 Immunovirotherapy Clinical Trial of Oncolytic HSV G207 to Treat Malignant Pediatric Cerebellar Brain Tumors. | Human gene therapy | 2020 | name in title: HSV G207 |
| PMID 28319448 | Rationale and Design of a Phase 1 Clinical Trial to Evaluate HSV G207 Alone or with a Single Radiation Dose in Children with Progressive or Recurrent Malignant Supratentorial Brain Tumors. | Human gene therapy. Clinical development | 2017 | name in title: HSV G207 |
| PMID 27512668 | Extended disease-free interval of 6 years in a recurrent glioblastoma multiforme patient treated with G207 oncolytic viral therapy. | Oncolytic virotherapy | 2015 | name in title: G207 |
| PMID 24572293 | A phase 1 trial of oncolytic HSV-1, G207, given in combination with radiation for recurrent GBM demonstrates safety and radiographic responses. | Molecular therapy : the journal of the American Society of Gene Therapy | 2014 | cited by trial NCT00157703 |
| PMID 18957964 | Phase Ib trial of mutant herpes simplex virus G207 inoculated pre-and post-tumor resection for recurrent GBM. | Molecular therapy : the journal of the American Society of Gene Therapy | 2009 | name in title: G207 |
| PMID 10845725 | Conditionally replicating herpes simplex virus mutant, G207 for the treatment of malignant glioma: results of a phase I trial. | Gene therapy | 2000 | name in title: G207 |
Unconfirmed matches (1)
Found by a weaker match (an ambiguous or short name, or a name only in the abstract); not counted. Corrections welcome.
| PubMed | Title | Journal | Year | Linked by |
|---|---|---|---|---|
| PMID 38215438 | The safety and accuracy of intratumoral catheter placement to infuse viral immunotherapies in children with malignant brain tumors: a multi-institutional study. | Journal of neurosurgery. Pediatrics | 2024 | name in abstract: G207 |
Other papers
Preclinical studies, reviews and other papers that name it, newest 100 shown.
| PubMed | Title | Journal | Year | Linked by |
|---|---|---|---|---|
| PMID 41108331 | The effect of oncolytic virotherapy on pediatric brain tumor- a systematic review. | Child's nervous system : ChNS : official journal of the International Society for Pediatric Neurosurgery | 2025 | name in abstract: HSV G207 |
| PMID 38183802 | Elucidating cellular response to treatment with viral immunotherapies in pediatric high-grade glioma and medulloblastoma. | Translational oncology | 2024 | name in abstract: HSV G207 |
| PMID 33911216 | HSV-1 G207 is active in paediatric glioma. | Nature reviews. Clinical oncology | 2021 | name in title: G207 |
| PMID 30918335 | Safety and efficacy of oncolytic HSV-1 G207 inoculated into the cerebellum of mice. | Cancer gene therapy | 2020 | name in title: G207 |
| PMID 32096291 | Folate-conjugated herpes simplex virus for retargeting to tumor cells. | The journal of gene medicine | 2020 | name in abstract: HSV G207 |
| PMID 30481622 | Stereotactic Placement of Intratumoral Catheters for Continuous Infusion Delivery of Herpes Simplex Virus -1 G207 in Pediatric Malignant Supratentorial Brain Tumors. | World neurosurgery | 2019 | name in title: G207 |
| PMID 31741780 | A novel in situ multiplex immunofluorescence panel for the assessment of tumor immunopathology and response to virotherapy in pediatric glioblastoma reveals a role for checkpoint protein inhibition. | Oncoimmunology | 2019 | name in abstract: HSV G207 |
| PMID 18957963 | Hypoxia enhances the replication of oncolytic herpes simplex virus. | Molecular therapy : the journal of the American Society of Gene Therapy | 2009 | name in abstract: HSV G207 |
| PMID 19116635 | Phase ib trial of oncolytic herpes virus G207 shows safety of multiple injections and documents viral replication. | Molecular therapy : the journal of the American Society of Gene Therapy | 2009 | name in title: G207 |
| PMID 17234749 | Angiogenic response caused by oncolytic herpes simplex virus-induced reduced thrombospondin expression can be prevented by specific viral mutations or by administering a thrombospondin-derived peptide. | Cancer research | 2007 | name in abstract: HSV G207 |
| PMID 17505980 | Effects of G207, a conditionally replication-competent oncolytic herpes simplex virus, on the developing mammalian brain. | Journal of neurovirology | 2007 | name in title: G207 |
| PMID 16163378 | Enhanced therapeutic efficacy of G207 for the treatment of glioma through Musashi1 promoter retargeting of gamma34.5-mediated virulence. | Gene therapy | 2006 | name in title: G207 |
| PMID 16475242 | Imaging and therapy of malignant pleural mesothelioma using replication-competent herpes simplex viruses. | The journal of gene medicine | 2006 | name in abstract: HSV G207 |
| PMID 16955534 | Enhanced therapeutic efficacy of oncolytic herpes vector G207 against human non-small cell lung cancer--expression of an RNA-binding protein, Musashi1, as a marker for the tailored gene therapy. | The journal of gene medicine | 2006 | name in title: G207 |
| PMID 15661558 | Combination of mutated herpes simplex virus type 1 (G207 virus) with radiation for the treatment of squamous cell carcinoma of the head and neck. | European journal of cancer (Oxford, England : 1990) | 2005 | name in title: G207 |
| PMID 15754306 | Enhanced efficacy of conditionally replicating herpes simplex virus (G207) combined with 5-fluorouracil and surgical resection in peritoneal cancer dissemination models. | The journal of gene medicine | 2005 | name in title: G207 |
| PMID 15059970 | Up-regulation of GADD34 mediates the synergistic anticancer activity of mitomycin C and a gamma134.5 deleted oncolytic herpes virus (G207). | FASEB journal : official publication of the Federation of American Societies for Experimental Biology | 2004 | name in title: G207 |
| PMID 15720798 | Multimutated herpes simplex virus g207 is a potent inhibitor of angiogenesis. | Neoplasia (New York, N.Y.) | 2004 | name in title: G207 |
| PMID 12670897 | Potent oncolytic activity of multimutated herpes simplex virus G207 in combination with vincristine against human rhabdomyosarcoma. | Cancer research | 2003 | name in title: G207 |
| PMID 11857031 | In situ cancer vaccination with a replication-conditional HSV for the treatment of liver metastasis of colon cancer. | Cancer gene therapy | 2002 | name in abstract: HSV G207 |
| PMID 11960286 | Immuno-viral therapy of brain tumors by combination of viral therapy with cancer vaccination using a replication-conditional HSV. | Cancer gene therapy | 2002 | name in abstract: HSV G207 |
| PMID 12219034 | Ionizing radiation potentiates the antitumor efficacy of oncolytic herpes simplex virus G207 by upregulating ribonucleotide reductase. | Surgery | 2002 | name in title: G207 |
| PMID 12386832 | Comparison of safety, delivery, and efficacy of two oncolytic herpes viruses (G207 and NV1020) for peritoneal cancer. | Cancer gene therapy | 2002 | name in title: G207 |
| PMID 11257700 | Treatment of human renal cell carcinoma by a conditionally replicating herpes vector G207. | The Journal of urology | 2001 | name in title: G207 |
| PMID 11312559 | Therapeutic efficacy of G207 in a novel peripheral nerve sheath tumor model. | Experimental neurology | 2001 | name in title: G207 |
| PMID 11319903 | Therapeutic efficacy of G207, a conditionally replicating herpes simplex virus type 1 mutant, for gallbladder carcinoma in immunocompetent hamsters. | Molecular therapy : the journal of the American Society of Gene Therapy | 2001 | name in title: G207 |
Unconfirmed matches (74)
Found by a weaker match (an ambiguous or short name, or a name only in the abstract); not counted. Corrections welcome.
| PubMed | Title | Journal | Year | Linked by |
|---|---|---|---|---|
| PMID 41705010 | A Decade of Oncolytic Virotherapy in Pediatric Cancers: A Systematic Review of Safety, Immune Awakening, and Emerging Efficacy. | Cureus | 2026 | name in abstract: G207 |
| PMID 41741902 | Clinical and translational progress in oncolytic virotherapy for pediatric CNS tumors. | Journal of neuro-oncology | 2026 | name in abstract: G207 |
| PMID 40805247 | Oncolytic Therapies for Glioblastoma: Advances, Challenges, and Future Perspectives. | Cancers | 2025 | name in abstract: G207 |
| PMID 41228258 | The Emerging Role of Oncolytic Virotherapy in Glioblastoma Management. | Cancers | 2025 | name in abstract: G207 |
| PMID 38724464 | Targeting NKG2D ligands in glioblastoma with a bispecific T-cell engager is augmented with conventional therapy and enhances oncolytic virotherapy of glioma stem-like cells. | Journal for immunotherapy of cancer | 2024 | name in abstract: G207 |
| PMID 38806994 | A viral attack on brain tumors: the potential of oncolytic virus therapy. | Journal of neurovirology | 2024 | name in abstract: G207 |
| PMID 39239066 | Synergistic effects of herpes oncolytic virus and cyclophosphamide for recurrent malignant glioma: a narrative review. | Annals of medicine and surgery (2012) | 2024 | name in abstract: G207 |
| PMID 39850819 | Rational strategies for designing next-generation oncolytic viruses based on transcriptome analysis of tumor cells infected with oncolytic herpes simplex virus-1. | Frontiers in oncology | 2024 | name in abstract: G207 |
| PMID 36634220 | Intraventricular immunovirotherapy; a translational step forward. | Oncotarget | 2023 | name in abstract: G207 |
| PMID 37749907 | Oncolytic virotherapies for pediatric tumors. | Expert opinion on biological therapy | 2023 | name in abstract: G207 |
| PMID 34004331 | Oncolytic viruses as a promising therapeutic strategy against the detrimental health impacts of air pollution: The case of glioblastoma multiforme. | Seminars in cancer biology | 2022 | name in abstract: G207 |
| PMID 35093451 | Gospel of malignant Glioma: Oncolytic virus therapy. | Gene | 2022 | name in abstract: G207 |
| PMID 35105718 | Immune Activity and Response Differences of Oncolytic Viral Therapy in Recurrent Glioblastoma: Gene Expression Analyses of a Phase IB Study. | Clinical cancer research : an official journal of the American Association for Cancer Research | 2022 | name in abstract: G207 |
| PMID 35487285 | Clinical advances in oncolytic virotherapy for pediatric brain tumors. | Pharmacology & therapeutics | 2022 | name in abstract: G207 |
| PMID 36239623 | Safety and Efficacy of Intraventricular Immunovirotherapy with Oncolytic HSV-1 for CNS Cancers. | Clinical cancer research : an official journal of the American Association for Cancer Research | 2022 | name in abstract: G207 |
| PMID 33663205 | Uncovering the Effect of pS202/pT205/pS208 Triple Phosphorylations on the Conformational Features of the Key Fragment G192-T212 of Tau Protein. | ACS chemical neuroscience | 2021 | name in abstract: G207 |
| PMID 29896663 | Oncolytic Virotherapy by HSV. | Advances in experimental medicine and biology | 2018 | name in abstract: G207 |
| PMID 30224769 | Enhanced Sensitivity of Patient-Derived Pediatric High-Grade Brain Tumor Xenografts to Oncolytic HSV-1 Virotherapy Correlates with Nectin-1 Expression. | Scientific reports | 2018 | name in abstract: G207 |
| PMID 30563466 | Oncolytic herpes simplex virus and immunotherapy. | BMC immunology | 2018 | name in abstract: G207 |
| PMID 28830653 | Recombinant human IgG1 based Fc multimers, with limited FcR binding capacity, can effectively inhibit complement-mediated disease. | Journal of autoimmunity | 2017 | name in abstract: G207 |
| PMID 26188016 | Pediatric medulloblastoma xenografts including molecular subgroup 3 and CD133+ and CD15+ cells are sensitive to killing by oncolytic herpes simplex viruses. | Neuro-oncology | 2016 | name in abstract: G207 |
| PMID 27215210 | Characterization and differential expression analysis of Toxocara canis aquaporin-1 gene. | Parasitology research | 2016 | name in abstract: G207 |
| PMID 27504936 | Crystal structures of spleen tyrosine kinase in complex with novel inhibitors: structural insights for design of anticancer drugs. | The FEBS journal | 2016 | name in abstract: G207 |
| PMID 25119379 | Assessment of oncolytic HSV efficacy following increased entry-receptor expression in malignant peripheral nerve sheath tumor cell lines. | Gene therapy | 2014 | name in abstract: G207 |
| PMID 21740360 | Targeted oncolytic herpes simplex viruses for aggressive cancers. | Current pharmaceutical biotechnology | 2012 | name in abstract: G207 |
| PMID 22015641 | Molecular network pathways and functional analysis of tumor signatures associated with development of resistance to viral gene therapy. | Cancer gene therapy | 2012 | name in abstract: G207 |
| PMID 22379082 | Preclinical evaluation of a genetically engineered herpes simplex virus expressing interleukin-12. | Journal of virology | 2012 | name in abstract: G207 |
| PMID 22299445 | Heterologously type IV pilus expressed protein of Burkholderia pseudomallei is immunogenic but fails to induce protective immunity in mice. | The Southeast Asian journal of tropical medicine and public health | 2011 | name in abstract: G207 |
| PMID 19829315 | Cellular effects of oncolytic viral therapy on the glioblastoma microenvironment. | Gene therapy | 2010 | name in abstract: G207 |
| PMID 20205051 | HSV-1-derived helper-independent defective vectors, replicating vectors and amplicon vectors, for the treatment of brain diseases. | Current opinion in drug discovery & development | 2010 | name in abstract: G207 |
| PMID 19455266 | Gateways to clinical trials. | Methods and findings in experimental and clinical pharmacology | 2009 | name in abstract: G207 |
| PMID 19526622 | Relationship between 31P metabolites and oncolytic viral therapy sensitivity in human colorectal cancer xenografts. | The British journal of surgery | 2009 | name in abstract: G207 |
| PMID 19693098 | Analysis of genetically engineered oncolytic herpes simplex viruses in human prostate cancer organotypic cultures. | Gene therapy | 2009 | name in abstract: G207 |
| PMID 19714803 | Structural and catalytic roles of residues located in beta13 strand and the following beta-turn loop in Fibrobacter succinogenes 1,3-1,4-beta-D-glucanase. | Biochimica et biophysica acta | 2009 | name in abstract: G207 |
| PMID 19967103 | Gateways to clinical trials. | Methods and findings in experimental and clinical pharmacology | 2009 | name in abstract: G207 |
| PMID 17981691 | Oncolytic virus therapy using genetically engineered herpes simplex viruses. | Frontiers in bioscience : a journal and virtual library | 2008 | name in abstract: G207 |
| PMID 18316577 | Synergy of a herpes oncolytic virus and paclitaxel for anaplastic thyroid cancer. | Clinical cancer research : an official journal of the American Association for Cancer Research | 2008 | name in abstract: G207 |
| PMID 18316582 | Oncolytic herpes simplex virus type-1 therapy in a highly infiltrative animal model of human glioblastoma. | Clinical cancer research : an official journal of the American Association for Cancer Research | 2008 | name in abstract: G207 |
| PMID 18551144 | Molecular analysis of human cancer cells infected by an oncolytic HSV-1 reveals multiple upregulated cellular genes and a role for SOCS1 in virus replication. | Cancer gene therapy | 2008 | name in abstract: G207 |
| PMID 18988803 | Ras signaling influences permissiveness of malignant peripheral nerve sheath tumor cells to oncolytic herpes. | The American journal of pathology | 2008 | name in abstract: G207 |
| PMID 19121697 | TBK1 does not play a role in the control of in vitro Burkholderia pseudomallei growth. | Transactions of the Royal Society of Tropical Medicine and Hygiene | 2008 | name in abstract: G207 |
| PMID 16990846 | Engineered herpes simplex virus expressing bacterial cytosine deaminase for experimental therapy of brain tumors. | Cancer gene therapy | 2007 | name in abstract: G207 |
| PMID 17235305 | Oncolytic HSV and erlotinib inhibit tumor growth and angiogenesis in a novel malignant peripheral nerve sheath tumor xenograft model. | Molecular therapy : the journal of the American Society of Gene Therapy | 2007 | name in abstract: G207 |
| PMID 17238803 | Augmented therapeutic efficacy of an oncolytic herpes simplex virus type 1 mutant expressing ICP34.5 under the transcriptional control of musashi1 promoter in the treatment of malignant glioma. | Human gene therapy | 2007 | name in abstract: G207 |
| PMID 17613221 | Oncolytic herpes simplex virus therapy for peripheral nerve tumors. | Neurosurgical focus | 2007 | name in abstract: G207 |
| PMID 17908985 | Herpes simplex virus Us3(-) mutant as oncolytic strategy and synergizes with phosphatidylinositol 3-kinase-Akt targeting molecular therapeutics. | Clinical cancer research : an official journal of the American Association for Cancer Research | 2007 | name in abstract: G207 |
| PMID 16179929 | Enhanced therapeutic efficacy of IL-12, but not GM-CSF, expressing oncolytic herpes simplex virus for transgenic mouse derived prostate cancers. | Cancer gene therapy | 2006 | name in abstract: G207 |
| PMID 16391370 | Effect of chemotherapy-induced DNA repair on oncolytic herpes simplex viral replication. | Journal of the National Cancer Institute | 2006 | name in abstract: G207 |
| PMID 16421599 | Development of a rapid method to generate multiple oncolytic HSV vectors and their in vivo evaluation using syngeneic mouse tumor models. | Gene therapy | 2006 | name in abstract: G207 |
| PMID 16574492 | Oncolytic viruses derived from the gamma34.5-deleted herpes simplex virus recombinant R3616 encode a truncated UL3 protein. | Molecular therapy : the journal of the American Society of Gene Therapy | 2006 | name in abstract: G207 |
| PMID 16627219 | Oncolytic herpes viral therapy is effective in the treatment of hepatocellular carcinoma cell lines. | Journal of gastrointestinal surgery : official journal of the Society for Surgery of the Alimentary Tract | 2006 | name in abstract: G207 |
| PMID 17167712 | Reovirus - possible therapy of cancer. | Neoplasma | 2006 | name in abstract: G207 |
| PMID 15735042 | Oncolytic herpes simplex virus vector therapy of breast cancer in C3(1)/SV40 T-antigen transgenic mice. | Cancer research | 2005 | name in abstract: G207 |
| PMID 15818382 | The potential of oncolytic virus therapy for pancreatic cancer. | Cancer gene therapy | 2005 | name in abstract: G207 |
| PMID 16158944 | Oncolytic herpesvirus with secretable angiostatic proteins in the treatment of human lung cancer cells. | Anticancer research | 2005 | name in abstract: G207 |
| PMID 16278413 | Oncolytic herpes simplex virus vector g47delta in combination with androgen ablation for the treatment of human prostate adenocarcinoma. | Clinical cancer research : an official journal of the American Association for Cancer Research | 2005 | name in abstract: G207 |
| PMID 34679293 | [Insights into a new weapon against cancer: oncolytic viruses]. | Virologie (Montrouge, France) | 2005 | name in abstract: G207 |
| PMID 14770080 | Augmentation of antitumor immune responses by multiple intratumoral inoculations of replication-conditional HSV and interleukin-12. | Journal of immunotherapy (Hagerstown, Md. : 1997) | 2004 | name in abstract: G207 |
| PMID 15000342 | Oncolytic viral therapy and immunotherapy of malignant brain tumors: two potential new approaches of translational research. | Annals of medicine | 2004 | name in abstract: G207 |
| PMID 15166969 | Utilizing tumor hypoxia to enhance oncolytic viral therapy in colorectal metastases. | Annals of surgery | 2004 | name in abstract: G207 |
| PMID 15185293 | Effect of murine liver cell proliferation on herpes viral behavior: implications for oncolytic viral therapy. | Hepatology (Baltimore, Md.) | 2004 | name in abstract: G207 |
| PMID 15300180 | Employing tumor hypoxia to enhance oncolytic viral therapy in breast cancer. | Surgery | 2004 | name in abstract: G207 |
| PMID 15349105 | Carcinoembryonic antigen directed herpes viral oncolysis improves selectivity and activity in colorectal cancer. | Surgery | 2004 | name in abstract: G207 |
| PMID 15383793 | Utilizing alpha-fetoprotein expression to enhance oncolytic viral therapy in hepatocellular carcinoma. | Annals of surgery | 2004 | name in abstract: G207 |
| PMID 12942152 | Immuno-viral therapy as a new approach for the treatment of brain tumors. | Drug news & perspectives | 2003 | name in abstract: G207 |
| PMID 14530377 | Targeting platelet-leukocyte interactions: identification of the integrin Mac-1 binding site for the platelet counter receptor glycoprotein Ibalpha. | The Journal of experimental medicine | 2003 | name in abstract: G207 |
| PMID 14682372 | Oncolytic viruses: clinical applications as vectors for the treatment of malignant gliomas. | Journal of neuro-oncology | 2003 | name in abstract: G207 |
| PMID 11916486 | Replication-selective herpes simplex virus type 1 mutant therapy of cervical cancer is enhanced by low-dose radiation. | Human gene therapy | 2002 | name in abstract: G207 |
| PMID 11956088 | Potent systemic antitumor activity from an oncolytic herpes simplex virus of syncytial phenotype. | Cancer research | 2002 | name in abstract: G207 |
| PMID 12218591 | Differential susceptibility of pediatric sarcoma cells to oncolysis by conditionally replication-competent herpes simplex viruses. | Journal of pediatric hematology/oncology | 2002 | name in abstract: G207 |
| PMID 12242723 | Oncolytic viral gene therapy for prostate cancer using two attenuated, replication-competent, genetically engineered herpes simplex viruses. | The Prostate | 2002 | name in abstract: G207 |
| PMID 12522436 | Oncolytic herpes simplex virus vectors for cancer virotherapy. | Cancer gene therapy | 2002 | name in abstract: G207 |
| PMID 11196154 | In situ expression of soluble B7-1 in the context of oncolytic herpes simplex virus induces potent antitumor immunity. | Cancer research | 2001 | name in abstract: G207 |
| PMID 11306480 | Biological purging of breast cancer cells using an attenuated replication-competent herpes simplex virus in human hematopoietic stem cell transplantation. | Cancer research | 2001 | name in abstract: G207 |
NIH grants
| Project | Title | Organisation | PI | Years | Linked by |
|---|---|---|---|---|---|
| R01FD006368 | Ph1 Study of HSV G207 in Pediatric Malignant Cerebellar Tumors IND 16294 01/05/18. | UNIVERSITY OF TX MD ANDERSON CAN CTR | FRIEDMAN, GREGORY K | 2019–2026 | name in title: HSV G207 |
| R44CA250883 | Phase II Clinical Trial of G207 HSV To Treat Children with High Grade Gliomas | TREOVIR, INC | GILLESPIE, GEORGE YANCEY | 2020–2023 | name in title: G207 |
| R01CA217179 | A Phase 1 Study of M032, a Genetically Engineered HSV-1 Expressing IL-12, in Patients with Recurrent/Progressive Glioblastoma Multiforme, Anaplastic Astrocytoma, or Gliosarcoma. | UNIVERSITY OF ALABAMA AT BIRMINGHAM | MARKERT, JAMES M | 2017–2019 | name in abstract: HSV G207 |
| R01FD005379 | Ph1 of HSV G207 and Radiation to Treat Pediatric Brain Tumors IND16294 (12/10/14) | UNIVERSITY OF ALABAMA AT BIRMINGHAM | FRIEDMAN, GREGORY K | 2016–2018 | name in title: HSV G207 |
| M01RR000032 | CT 2001 A STAGED PHASE I STUDY OF THE TREATMENT OF MALIGNANT GLIOMA WITH G207, | UNIVERSITY OF ALABAMA AT BIRMINGHAM | MARKERT, JAMES M | 1999–2007 | name in title: G207 |
Unconfirmed matches (18)
Found by a weaker match (an ambiguous or short name, or a name only in the abstract); not counted. Corrections welcome.
| Project | Title | Organisation | PI | Years | Linked by |
|---|---|---|---|---|---|
| P01CA163205 | Project 3: Circumventing extracellular Adenosine barrier to oncolytic virotherapy | BRIGHAM AND WOMEN'S HOSPITAL | KAUR, BALVEEN | 2023–2026 | name in project terms: G207 |
| P30CA013148 | 03 - Neuro-Oncology | UNIVERSITY OF ALABAMA AT BIRMINGHAM | NABORS, LOUIS B | 2022–2026 | name in abstract: G207 |
| R01NS146081 | Targeting RNF2 to Synergize with Oncolytic Immunovirotherapy to Induce Anti-Cancer Immunity in Medulloblastoma | UNIVERSITY OF TX MD ANDERSON CAN CTR | FRIEDMAN, GREGORY K | 2026–2026 | name in abstract: G207 |
| R33NS128191 | Development of murine glioblastoma model for oncolytic HSV therapy | LSU HEALTH SCIENCES CENTER | KAUR, BALVEEN | 2026–2026 | name in abstract: G207 |
| R61NS128191 | Development of murine glioblastoma model for oncolytic HSV therapy | AUGUSTA UNIVERSITY | KAUR, BALVEEN | 2024–2025 | name in abstract: G207 |
| U19CA264512 | An engineered oncolytic herpes virus expressing a full-length α-CD47 mAb for the treatment of GBM | BECKMAN RESEARCH INSTITUTE/CITY OF HOPE | BADIE, BEHNAM | 2021–2025 | name in project terms: G207 |
| UM1CA081457 | Pediatric Brain Tumor Consortium A multi-institutional consortium devoted to novel phase I and II clinical evaluations of experimental treatment approaches for pediatric CNS tumors | ST. JUDE CHILDREN'S RESEARCH HOSPITAL | ONAR-THOMAS, ARZU | 2025–2025 | name in project terms: G207 |
| R03NS128449 | Targeting Acid Ceramidase to Improve the Efficacy of Herpes Oncolytic Virus | UNIVERSITY OF ALABAMA AT BIRMINGHAM | HJELMELAND, ANITA BORTON | 2022–2023 | name in project terms: G207 |
| R33NS112410 | Optimizing oncolytic virus therapy for glioblastoma | AUGUSTA UNIVERSITY | KAUR, BALVEEN | 2022–2022 | name in abstract: G207 |
| R01CA150153 | Enhancing viral oncolysis with vasculostatin gene delivery | UNIVERSITY OF TEXAS HLTH SCI CTR HOUSTON | KAUR, BALVEEN | 2016–2020 | name in abstract: G207 |
| R61NS112410 | Optimizing oncolytic virus therapy for glioblastoma | UNIVERSITY OF TEXAS HLTH SCI CTR HOUSTON | KAUR, BALVEEN | 2019–2020 | name in abstract: G207 |
| F31CA192453 | Oncolytic Herpes Simplex Virus Interactions with Glioblastoma Stem Cells | HARVARD MEDICAL SCHOOL | PETERS, COLE WINSTEAD DYLAN | 2015–2017 | name in project terms: G207 |
| P01CA071933 | Engineered HSV For Treatment of Malignant Glioma | UNIVERSITY OF ALABAMA AT BIRMINGHAM | WHITLEY, RICHARD J. | 2009–2013 | name in abstract: G207 |
| P01NS040923 | Vector delivery to modify the brain tumor and its microenvironment | UNIVERSITY OF PITTSBURGH AT PITTSBURGH | GLORIOSO, JOSEPH C | 2008–2012 | name in abstract: G207 |
| P01CA080124 | Improving Interstitial Transport in Tumors | MASSACHUSETTS GENERAL HOSPITAL | JAIN, RAKESH K. | 2007–2010 | name in project terms: G207 |
| R01CA119298 | Glioma Therapy Using Targeted Oncolytic HSV Vectors | UNIVERSITY OF PITTSBURGH AT PITTSBURGH | GLORIOSO, JOSEPH C | 2006–2010 | name in abstract: G207 |
| R01CA083066 | IMAGING TRANSGENE EXPRESSION IN GENE THERAPY PROTOCOLS | SLOAN-KETTERING INST CAN RESEARCH | BLASBERG, RONALD G | 2002–2004 | name in abstract: G207 |
| R01NS032677 | GENETICALLY ENGINEERED VIRUSES FOR BRAIN TUMOR THERAPY | MASSACHUSETTS GENERAL HOSPITAL | MARTUZA, ROBERT L | 1998–2002 | name in abstract: G207 |
Notes
Second-generation oHSV; first-in-human glioma trial 1998-2000 (Markert et al.). Paediatric trials run by the University of Alabama at Birmingham and the Pediatric Brain Tumor Consortium. A planned phase 2 (NCT04482933) was withdrawn.
How to cite
G207 (AXP000074.1). The Abstractinator program registry, release 2026-11-17+2c46e992acfc. https://abstractinator.me/registry/AXP000074.html
Something wrong or missing? Suggest a correction (a GitHub issue; please link your evidence). Entry created 2026-11-11, updated 2026-11-11.